Janux Q1 2026 net loss $24.4M; cash $956.4M; discontinues JANX008, initiates JANX014

Janux Therapeutics, Inc.

2026-Q1 EPS reported -$0.39 revenue$3,733,000

Net loss of $24.4M for Q1 2026 vs $23.5M YoY; cash and investments at $956.4M.
Discontinued JANX008 (EGFR-TRACTr) development after Phase 1a; resources redirected.
Initiated clinical evaluation of JANX014 (PSMA-TRACTr); JANX007 combination with darolutamide enrolling.
BMS collaboration milestone triggered $35M payment upon development candidate nomination.
Appointed William Go, M.D., Ph.D. as Chief Medical Officer.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Janux Therapeutics, Inc. reported the quarter ended March 31, 2026 results: net income Net loss was $24.4 million for the quarter ended March 31, 2026.

Period: the quarter ended March 31, 2026
Net income: Net loss was $24.4 million for the quarter ended March 31, 2026
Result: reported results

Exact text from the filing

Janux Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2026.

View on SEC.gov

Browse all earnings releases →

Janux Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-211964

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.